Comment

  • 1 March 2018

    Increasing dose outsourcing masks long-term concerns

    In 2017, outsourced dose manufacturing of new molecular entities (NMEs) reached its highest level since 2014. Coupled with the well-documented increase in overall new drug applications (NDAs) approved by the...

Close
Close
Close

Go Top